JPWO2020148527A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020148527A5 JPWO2020148527A5 JP2021540822A JP2021540822A JPWO2020148527A5 JP WO2020148527 A5 JPWO2020148527 A5 JP WO2020148527A5 JP 2021540822 A JP2021540822 A JP 2021540822A JP 2021540822 A JP2021540822 A JP 2021540822A JP WO2020148527 A5 JPWO2020148527 A5 JP WO2020148527A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- sar6
- peptide ligand
- cysteine residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 239000003446 ligand Substances 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 19
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 8
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002062 molecular scaffold Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- IFPQOXNWLSRZKX-UHFFFAOYSA-N 2-amino-4-(diaminomethylideneamino)butanoic acid Chemical group OC(=O)C(N)CCN=C(N)N IFPQOXNWLSRZKX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900527.1 | 2019-01-15 | ||
| GBGB1900527.1A GB201900527D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for integrin avb3 |
| PCT/GB2020/050071 WO2020148527A1 (en) | 2019-01-15 | 2020-01-15 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518210A JP2022518210A (ja) | 2022-03-14 |
| JP2022518210A5 JP2022518210A5 (https=) | 2023-01-25 |
| JPWO2020148527A5 true JPWO2020148527A5 (https=) | 2023-01-25 |
Family
ID=65528151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540822A Pending JP2022518210A (ja) | 2019-01-15 | 2020-01-15 | インテグリンαｖβ３に特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220064221A1 (https=) |
| EP (1) | EP3966233A1 (https=) |
| JP (1) | JP2022518210A (https=) |
| CN (1) | CN113439088A (https=) |
| GB (1) | GB201900527D0 (https=) |
| WO (1) | WO2020148527A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900528D0 (en) * | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for integrin AVB3 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| WO2011079015A1 (en) * | 2009-12-21 | 2011-06-30 | The Regents Of The University Of California | Rgd-containing cyclic peptides |
| US20140274759A1 (en) * | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| GB201810329D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
-
2019
- 2019-01-15 GB GBGB1900527.1A patent/GB201900527D0/en not_active Ceased
-
2020
- 2020-01-15 CN CN202080014773.9A patent/CN113439088A/zh active Pending
- 2020-01-15 JP JP2021540822A patent/JP2022518210A/ja active Pending
- 2020-01-15 EP EP20701120.6A patent/EP3966233A1/en not_active Withdrawn
- 2020-01-15 US US17/422,935 patent/US20220064221A1/en not_active Abandoned
- 2020-01-15 WO PCT/GB2020/050071 patent/WO2020148527A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020148527A5 (https=) | ||
| Zhang et al. | Converting peptides into drug leads by lipidation | |
| JP5908000B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JPWO2020148528A5 (https=) | ||
| JPWO2020148525A5 (https=) | ||
| JP2023029957A (ja) | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 | |
| JP2008525491A5 (https=) | ||
| JP2014111628A (ja) | ウイルス融合のインヒビターのコレステロール誘導体 | |
| JPWO2020120980A5 (https=) | ||
| KR20190062496A (ko) | 조절 방출 pth 화합물을 위한 투여 용법 | |
| JPWO2021019244A5 (https=) | ||
| JPWO2020128527A5 (https=) | ||
| JPWO2020148526A5 (https=) | ||
| JPWO2020120981A5 (https=) | ||
| JPWO2020120983A5 (https=) | ||
| WO1991018010A1 (en) | Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof | |
| JPWO2020148529A5 (https=) | ||
| Redman et al. | Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery | |
| CN107207578A (zh) | 用于治疗癌症和血管生成相关疾病的CD44v6‑衍生的环肽 | |
| JPWO2020120984A5 (https=) | ||
| JP2023145635A (ja) | 免疫調節特性を有するペプチド | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| CN100413883C (zh) | 选择性地与p-选择蛋白结合的肽化合物 | |
| JP6583411B2 (ja) | 薬物複合体 | |
| JP2025520703A (ja) | 修飾型アミノ酸及びその使用 |